macroglobulinemia

(redirected from Waldenstrom's macroglobulinemia)
Also found in: Dictionary, Medical, Wikipedia.
Related to Waldenstrom's macroglobulinemia: multiple myeloma, lymphoplasmacytic lymphoma

macroglobulinemia

[‚mak·rə‚gläb·yə·lə′nē·mē·ə]
(medicine)
Abnormal increase in macroglobulins in the blood.
A disease characterized by proliferation of lymphocytes and plasmocytes and abnormally high macroglobulin blood levels.
References in periodicals archive ?
The clinical data for ibrutinib in Waldenstrom's macroglobulinemia showed that it was highly active for these previously-treated patients, giving durable responses with an acceptable safety and tolerability profile.
Pathogenesis and morbidity of autoantibody syndromes in Waldenstrom's macroglobulinemia.
Waldenstrom's macroglobulinemia is a slow-growing, rare type of B-cell lymphoma for which no approved treatments is present in the EU at present.
Update on treatment recommendations from the fourth international workshop on Waldenstrom's macroglobulinemia.
A 72-year-old man with a history of Parkinson's disease and newly diagnosed Waldenstrom's macroglobulinemia was admitted to the hospital after he had undergone treatment with plasmapheresis and rituximab, a chimeric monoclonal antibody (dose 2 of 4).
That's because Schaible has a rare cancer called Waldenstrom's macroglobulinemia.
The initial NCI-sponsored studies will explore blinatumomab's utility as a first-line treatment for patients newly diagnosed with ALL, older patients with ALL, and patients with Waldenstrom's macroglobulinemia.
About IMBRUVICA IMBRUVICA is currently approved for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, CLL patients who have del 17p and patients with Waldenstrom's macroglobulinemia.
In fact, since coming to Baylor, Marvin has published 214 more papers, including research on many aspects of hematology and immunology--antitumor antibodies, Waldenstrom's macroglobulinemia, monoclonal antibodies, graft-versus-host disease, multiple myeloma, amyloidosis, and transplantation.
Memorial contributions may be sent in his memory to International Waldenstrom's Macroglobulinemia Foundation, 6144 Clark Avenue, Sarasota, FL, 34238 www.
Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID[R] for the treatment of Waldenstrom's macroglobulinemia, a rare subtype of B-cell non-Hodgkin's lymphoma.